Key messages Q3 2022
Solid results in an increasingly challenging market environment

Solid results in an increasingly challenging market environment:
Adj. EBITDA of €615 m in Q3 – supported by a strong Specialty Additives performance (+8% yoy)

Volumes decline, pricing holding up: Double-digit price increases across all growth divisions resulting in ongoing successful pass-on of higher variable costs

Cash generation picking up with FCF of €288 m in Q3; further significant NWC improvement expected in Q4 to achieve ~30% cash conversion for the full year

Outlook for FY 2022 confirmed: Adj. EBITDA between €2.5 and 2.6 bn

Structural support for 2023: Resilient & regionally balanced portfolio setup, progress in Performance Materials divestment, high visibility on energy costs & gas supply, contingency measure toolbox in implementation
Table of contents

1. Evonik at a glance

2. Strategy

3. Capital allocation & financial targets

4. Financials Q3 2022
Leading Beyond Chemistry – Our purpose
Evonik on the way to become a best-in-class specialty chemicals company

- Leading market positions in 80% of our business
- Leading key financial indicators
- Connecting skills and perspectives
- Develop solutions together with partners
- Sustainability key driver of growth
- Clear focus on specialty chemicals
- Target 100% specialty portfolio

Video “We are Evonik”
Evonik well equipped as “Enabler of Sustainable Change”
Portfolio circled around our four “Sustainability Focus Areas”

**ENSURE HEALTH & WELL-BEING**

**DRUG DELIVERY SYSTEMS**
- Advanced oral & parenteral drug delivery systems (e.g. mRNA LNP)

**SPECIALTY ADDITIVES**
- for environmentally-friendly solutions, e.g. water-based artificial leather

**CIRCULAR ECONOMY**
- Circular plastic & circular polyurethanes additive solutions

**FUTURE MOBILITY**
- Lightweight solutions
- Solutions for hybrid & full battery cars

**FIGHT CLIMATE CHANGE**

**ECO-SOLUTIONS**
- Specialty peroxides solutions
- Membranes for gas separation

**BIO-BASED SOLUTIONS**
- Bio-based & fully bio-degradable surfactants
- Natural active cosmetics ingredients

**SUSTAINABLE NUTRITION**
- Omega-3 fatty acids from natural marine algae
- Gut health solutions

**SAFE GUARD ECOSYSTEMS**

**DRIVE CIRCULARITY**

**Leading Beyond Chemistry**
Leading Beyond Chemistry – Growth divisions
Specialty chemicals portfolio with strong positioning and attractive financials

**Specialty Additives**
Wide range of additives for **maximum performance** which make the key difference

- Sales: €3,710 m
- Margin: 25%
- ROCE: 18%

**Nutrition & Care**
Sustainable solutions for basic human needs in **resilient end markets** like pharma, personal care and animal nutrition

- Sales: €3,557 m
- Margin: 20%
- ROCE: 12%

**Smart Materials**
Innovative materials that enable **environmentally-friendly solutions** for mobility, environment and urbanization

- Sales: €3,918 m
- Margin: 17%
- ROCE: 8%

1: FY 2021

January 2023 | Evonik Q3 2022 Company Presentation
Leading Beyond Chemistry – Growth divisions
Ambition and promising growth drivers

<table>
<thead>
<tr>
<th>Specialty Additives</th>
<th>Nutrition &amp; Care</th>
<th>Smart Materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Small amount – Big effect”</td>
<td>“Bringing Nutrition &amp; Care to Life – for life and living”</td>
<td>“We find solutions for the needs of today and tomorrow”</td>
</tr>
</tbody>
</table>

**Ambition**

- “Small amount – Big effect”

**… and promising growth drivers**

- Making the difference
- Enabling circular economy
- Digital solutions

- Active cosmetics ingredients
- Drug delivery systems
- Sustainable & healthy nutrition

- Future Mobility
- Eco-Solutions

January 2023 | Evonik Q3 2022 Company Presentation
Next Generation Evonik: Embarking on the next phase of our transformation
Sustainability fully integrated into all three strategic levers

Three major strategic levers...

Next Generation Portfolio
+ Exit Performance Materials
+ Full focus on three attractive growth divisions

Next Generation Innovation
+ €1 bn new sales well on track
+ Growth areas beyond 2025 launched

Next Generation Culture
+ Diversity as key to successful strategy execution
+ ESG targets integrated into mgmt. compensation

... with sustainability fully integrated ...

ESG Targets
+ >50% sales share of NEXTGEN Solutions
+ -25% CO₂ emission reduction, e.g. via NEXTGEN Technologies

Financial Targets
+ Organic growth >4%
+ EBITDA margin 18-20%
+ ROCE >11%
+ FCF Conversion >40%

... delivering on ambitious targets

1. Until 2030

January 2023 | Evonik Q3 2022 Company Presentation
Leading in Innovation – Growth fields and sales target
On track to achieve target of >€1 bn sales from innovation

Innovation Growth Fields
- Advanced Food Ingredients
- Additive Manufacturing
- Sustainable Nutrition
- Cosmetic Solutions
- Membranes
- Healthcare Solutions

Sizeable sales base established in all growth fields
Above-average margin contribution

Sales contribution Innovation Growth Fields
- 25% p.a. (CAGR)
- >40%
- >500

> €1 bn by 2025

January 2023 | Evonik Q3 2022 Company Presentation
Evonik aligned to sustainability

Sustainability as part of portfolio and strategic management processes

**Excellent Rankings**

Evonik amongst leaders in all relevant ratings – “AA” MSCI ESG rating, EcoVadis “Platin” rating, “B-” ISS Oekom and “A-” CDP rating

**Environmental Targets**

-25% reduction of scope 1 and scope 2 emission until 2030 (vs. 2021)

**Ambitious environmental targets**

Evonik’s sustainability strategy with ambitious targets

Evonik will be climate neutral by 2050

**Portfolio Management**

~37% Next Generation Solutions

Sales share with solutions with a clearly positive sustainability profile; target of >50% by 2030
# Leading Beyond Chemistry

**Summary of key financial & ESG targets**

## Financial Targets

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organic sales CAGR</td>
<td>&gt;4%</td>
</tr>
<tr>
<td>EBITDA margin</td>
<td>18-20%</td>
</tr>
<tr>
<td>Cash conversion ratio</td>
<td>&gt;40%</td>
</tr>
<tr>
<td>ROCE</td>
<td>~11%</td>
</tr>
<tr>
<td>Reliable &amp; sustainably growing dividend</td>
<td></td>
</tr>
<tr>
<td>Solid investment grade rating</td>
<td></td>
</tr>
</tbody>
</table>

## ESG Targets

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accident frequency rate&lt;sup&gt;1&lt;/sup&gt;</td>
<td>≤0.26</td>
</tr>
<tr>
<td>“Next Generation Solutions”&lt;sup&gt;2&lt;/sup&gt;</td>
<td>&gt;50%</td>
</tr>
<tr>
<td>Sales Inno. Growth Fields&lt;sup&gt;3&lt;/sup&gt;</td>
<td>&gt;€1 bn</td>
</tr>
<tr>
<td>GHG emissions (scope 1&amp;2)&lt;sup&gt;4&lt;/sup&gt;</td>
<td>-25%</td>
</tr>
<tr>
<td>Gender diversity&lt;sup&gt;5&lt;/sup&gt;</td>
<td>23%</td>
</tr>
<tr>
<td>Intercultural mix&lt;sup&gt;6&lt;/sup&gt;</td>
<td>20%</td>
</tr>
</tbody>
</table>

---

1. Indicator per 200,000 working hours | 2. Sales share by 2030 | 3. by 2025

January 2023 | Evonik Q3 2022 Company Presentation
Table of contents

1. Evonik at a glance
2. Strategy
3. Capital allocation & financial targets
4. Financials Q3 2022
Portfolio transformation – More balanced and more specialty
Portfolio quality significantly improved – today ~80% specialty businesses

Adj. EBITDA operating businesses

Portfolio characteristics

- Specialty businesses now represent ~80% of EBITDA
- Specialty businesses with 10-year track record of 3pp higher annual organic earnings growth¹


¹: organic EBITDA CAGR Specialty vs. Total Operating Businesses (excl. M&A) 2011 – 2021

January 2023 | Evonik Q3 2022 Company Presentation
Portfolio transformation – Clear portfolio roles
Focus on three growth divisions - Exit Performance Materials

- Specialty Additives
- Nutrition & Care
- Smart Materials
- Performance Materials

Growth focus

- Strong innovation pipeline: ~4% R&D/sales
- High sustainability focus: Expand portfolio share of “Next Generation Solutions”
- Targeted M&A in complementary products and technologies
- Selected efficiency measures to strengthen cost leadership and improve portfolio quality

Exit

- Aiming to find new owners/partners for the businesses in the course of 2023
- Performance Materials to be ceased thereafter
**Portfolio: Full focus on three attractive growth divisions**

**Investments in R&D, organic & inorganic growth**

---

**Specialty Additives**

- **Additive Technologies**
  - Modular expansion of Silicones & Amine platforms via >€100 m investments (2022 – 2024)
  - Addition of new effects, functionalities and technology platforms to Additives portfolio

---

**Nutrition & Care**

- **Drug Delivery Systems**
  - mRNA: Sizeable investments into lipids, formulation and fill-finish

- **Care Solutions**
  - Three-digit million € investment into world’s first industrial-scale biosurfactants production (start-up 2023/24)
  - Targeting market leadership in Active Cosmetics Ingredients market by 2025 via organic growth and M&A

---

**Smart Materials**

- **Membranes**
  - Modular investments into capacity expansion for gas-filtering membranes (~€50 m)
  - Breakthrough of electrolytic production of green hydrogen via DURAION® AEM membranes

- **Specialty Peroxides Solutions**
  - Investments into purification capacities to capture growth potential of Specialties applications
  - Growth option in highly efficient and sustainable HP+ technologies (HPPO, HPPG)
 Portfolio transformation – Active M&A management
Decisive and value-accretive portfolio management

<table>
<thead>
<tr>
<th>Divestments</th>
<th>Acquisitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>~€2 bn cyclical sales</td>
<td>&gt;€2 bn resilient sales</td>
</tr>
<tr>
<td>sold at attractive valuation (8.5x EV/EBITDA)</td>
<td>Ø multiple of 9.1x EV/EBITDA (incl. synergies)</td>
</tr>
<tr>
<td>Ø EBITDA margin: ~15%¹</td>
<td>Ø EBITDA margin: ~22%</td>
</tr>
<tr>
<td></td>
<td>Delivery of synergies on track (€80 m by end of 2020)</td>
</tr>
</tbody>
</table>

Decisive and value-accretive portfolio management

- Portfolio cyclicity & Capex intensity reduced
- More resilient EBITDA margin and improved cash profile

Divestments: Methacrylates business sold for EV of €3 bn (8.5x EV/EBITDA) in 07/2019
Acquisitions: Air Products specialty additives business for US$3.8 bn (9.9x EV/EBITDA incl. synergies & tax benefits) in 01/2017 | Dr. Straetmans cosmetics business in 05/2017
Huber Silica business for US$630 m (~7x EV/EBITDA incl. synergies & tax benefits) in 09/2017 | PeroxyChem for US$640 m (7.6x EV/EBITDA incl. synergies) in 02/2020 | Porocel for US$210 m (9.1x EV/EBITDA) in 11/2020

¹: 2014-2019
Portfolio: Exit of Performance Materials in execution
Transformation for all three business lines ongoing

- Superabsorber
  - ~ €700 m sales<sup>1</sup>
  - Carve-out completed July 1<sup>st</sup> 2021
  - Value-enhancing start of divestment process on the basis of improved 2022 financials and positive 2023 outlook

- Functional Solutions
  - ~ €450 m sales<sup>1</sup>
  - Divestment process for Lülsdorf site (~ €150 m sales) initiated in 2021
  - Alkoxides (biodiesel catalysts; ~ €300 m sales) to become part of Evonik growth divisions

- Performance Intermediates
  - ~ €1,800 m sales<sup>1</sup>
  - Process to find strong new partner for the business to be initiated in H2 2022
  - Joint venture as preferred intermediate step for full divestment

Aiming to find new owners/partners for each of the three businesses in the course of 2023
Division Performance Materials to be ceased thereafter

---

<sup>1</sup> FY 2021
RD&I at Evonik

Facts & Figures

>€450 m SPENT

>€500 m SALES IN 2021 FROM INNOVATION GROWTH FIELDS

~24,000 PATENTS

>€2,500 EMPLOYEES

100% SUSTAINABILITY-INTEGRATED

1. Patents and patents pending

January 2023 | Evonik Q3 2022 Company Presentation
**RD&I organization**
Continuous exchange across the entire Evonik organization

**RD&I Council**

**Research, Development & Innovation**

<table>
<thead>
<tr>
<th>Divisional RD&amp;I</th>
<th>Business Incubation</th>
<th>Venturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialty Additives</td>
<td>Creavis</td>
<td>Evonik Venture Capital</td>
</tr>
<tr>
<td>Nutrition &amp; Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smart Materials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance Materials</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Consistent focus on the same strategic direction as a Group**

**Knowledge sharing and use of different technology platforms**

**Efficient use of resources and competencies; flexible setup of interdisciplinary project teams**

**Full integration of sustainability criteria into decision making and allocation of resources**
Sustainability as backbone of Evonik’s purpose and strategy
Clear commitment to growing handprint and reducing footprint

**Sustainability is an integral part of our purpose**

“Sustainability is a key growth driver and the cornerstone of our product portfolio, our investments and our innovation management.”

“We see profitable growth and assuming responsibility as **two sides of the same coin.**”

**Core elements of our sustainability approach**

1. Evonik fully integrates sustainability in its Strategic Management Process

2. Evonik intends to **increase the portfolio share** of products with **sustainability benefits**

3. Evonik is committed to foresighted resource management

4. Evonik with high standards for **governance** and continuous **improvement of its reporting**

**Key growth driver…**

Our Handprint

“Sustainability is a key growth driver and the cornerstone of our product portfolio, our investments and our innovation management.”

**…and saving resources**

Our Footprint

“We take responsibility by caring about our resources.”

January 2023 | Evonik Q3 2022 Company Presentation
Ambitious commitments on handprint and footprint
In line with Science Based Targets

**NEXTGEN Solutions**

- **Next Gen Solution**
  - (Leaders + Drivers)
  - >50% Sales by 2030

- **Challenged Products**
  - <5%

**NEXTGEN Technologies**

- **Scope 1+2**
  - (Well below 2 degrees)
  - -25% CO₂ reduction 2030

- **Scope 3**
  - (2 degrees, committed)
Handprint: “Next Generation Solutions”
37% of Evonik’s portfolio with superior sustainability benefits

**Result of PSA analysis**

- **Leader (A++)** & **Driver (A+)**
- **Challenged (C--)**
- **Transiotor (C-)**

- **External sales**
  - ~90% products above or on market reference
  - **Performer (B)** 53%

**Best-in-class products in Evonik’s portfolio which…**

- …deliver **superior sustainability benefits** to our customers
- …deliver **above-average growth**
- …address increasing customer demand for sustainable solutions

NGS: “Next Generation Solutions” include “Leader” (A++) and “Driver” (A+) products and solutions
Handprint: “Next Generation Solutions” to grow beyond 50% by 2030
Ambitious new sales share target to be achieved through three levers

Increase “Next Generation Solutions”

Three levers to increase the share of NGS

- Existing “Next Generation Solutions” with superior sales growth rates
- New sales from innovations becoming “Next Generation Solutions”
- “Challenged” and “Transitioner” products exiting or with new formulations

1. NGS: “Next Generation Solutions” include “Leader” (A++) and “Driver” (A+) products and solutions

January 2023 | Evonik Q3 2022 Company Presentation
Handprint: Above-average growth of “Next Generation Solutions”
Selected examples addressing our four Sustainability Focus Areas

- Lightweight applications: PA12 portfolio
- Batteries: additives for electrodes / separators
- "Green tire" technology

- Global development partner & solutions provider for delivery systems for effective drugs and vaccinations
- Evonik as pioneer in Lipid Nano Particle (LNP) field for mRNA technology

- Additives for durability in construction
  - Water-repellents for building materials
  - Additives for integrated protection and self-healing of concrete structures

- Future Mobility solutions

- Additives for integrated protection and self-healing of concrete structures
- High-quality proteins with essential amino acids
- Production of omega-3 fatty acids from microalgae
- AQUAVI® Met-Met as methionine source for shrimp and prawns

- Drug Delivery Systems

- Modern aquaculture solutions

% values: Target CAGR 2021-2030 defined in Strategy Dialogue

24  January 2023  |  Evonik Q3 2022 Company Presentation
Footprint: Commitments to reaching the Paris Climate Agreement
Evonik will be climate neutral by 2050. Committed to SBTi.

Achievements on GHG emissions’ reduction

Scope 1&2

- 2021: -43%

New targets for GHG emissions scope 1&2

Scope 1&2
Well below 2°C

Scope 3
Committed

- 2030: -25%
- 2050: -100%

1. Net emissions (= gross emissions minus power and steam sold externally); reference year 2008; on initial -50% target by year 2025
2. Commitment letter signed and handed in for SBTi, 25th April 2022
3. Gross emissions; reference year 2021, target year 2030

9.500 5.450
2008 2021

6.450 5.800 4.850
2021 2025 2030 2050

January 2023 | Evonik Q3 2022 Company Presentation
Footprint: Long-term PPA signed with EnBW
Covering 25% of European electricity needs of Evonik with wind energy

- PPA signed with EnBW for a new North Sea offshore wind park starting in 2026
- Delivery of 0.4 TWh to Evonik
- Covering 25% of Evonik's European electricity needs (~100 kt CO$_2$ emission reduction p.a.)
- Fixed conditions over 15 years (duration of contract)

Significantly reducing dependency on availability and prices of conventional energy sources
Complementing the governance on ESG
Reflected in organizational set-up and remuneration

**Clear responsibilities**
- Executive Board has overall responsibility for sustainability
- Setting strategic framework and executing measures in close cooperation with operating divisions

**Part of remuneration**
- Occupational safety part of remuneration of the executive board since more than a decade
- New ESG goals to be integrated in remuneration schemes of Executive Board

- Long-term incentives based on strategic ESG KPIs, e.g.:
  - Sales share of “Next Generation Solutions”
  - CO₂ emission reduction

New element for approval at AGM 2022
Our Purpose inspires us

Our Values guide us

Safety first as foundation:
- Accident frequency as part of management compensation
- Low level secured over the last years

Diversity as basis of our economic success:
- Ambitious targets defined
- Inclusive mindset and behavior ultimately utilize diversity successfully

Attractive employer:
- Employee commitment with increase of 5 pp in latest employee survey

1. below upper limit of 0.26 (number of accidents per 200,000 working hours)
Table of contents

1. Evonik at a glance
2. Strategy
3. Capital allocation & financial targets
4. Financials Q3 2022
## Financial targets
### Evonik Group

<table>
<thead>
<tr>
<th>Mid-term Financial Targets</th>
<th>Revised targets (excl. PM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above-average volume growth in growth divisions (&gt;3%)</td>
<td>Organic sales CAGR &gt;4%</td>
</tr>
<tr>
<td>EBITDA margin in the range of 18-20%</td>
<td>EBITDA margin in the range of 18-20%</td>
</tr>
<tr>
<td>Cash conversion ratio of &gt;40%</td>
<td>Cash conversion ratio of &gt;40%</td>
</tr>
<tr>
<td>ROCE ~11% - well above cost of capital</td>
<td>ROCE ~11% - well above cost of capital</td>
</tr>
<tr>
<td>Reliable and sustainably growing dividend</td>
<td>Reliable and sustainably growing dividend</td>
</tr>
<tr>
<td>Solid investment grade rating</td>
<td>Solid investment grade rating</td>
</tr>
</tbody>
</table>

Unchanged:
- ROCE ~11% - well above cost of capital
- Reliable and sustainably growing dividend
- Solid investment grade rating
## Financial targets
By growth division

<table>
<thead>
<tr>
<th>Specialty Additives</th>
<th>Nutrition &amp; Care</th>
<th>Smart Materials</th>
</tr>
</thead>
</table>
| **Next Generation Solutions**
EBITDA margin
Secure strong level (2021: 25%) | Secure strong level (2021: 20%) | Secure strong level (2021: 17%) |
| **ROCE**
Secure strong level (2021: 18%) | > 14% (2021: 12%) | > 11% (2021: 8%) |
| > 40% | > 50% | > 50% |
| > 22% | > 14% | ~ 20% |

1: Products and solutions with a clearly positive sustainability profile that is above or well above the market reference level
Capital allocation into our green transformation
Priority on growth investments and targeted M&A

Significant cash inflow …

Increasing Operating Cash Flow
Attractive cash conversion with steadily growing earnings

Divestment proceeds Performance Materials

… invested into our green transformation

>€3 bn
2022-2030

- Growth investments into our sustainability leaders
- Attractive growth rates and returns (IRR >11%)

NEXTGEN Solutions

~€700 m
2022-2030

- Investments into infrastructure, production and processes
- Significant energy & emissions reduction as well as reduction of operating costs (>€100 m by 2030)

NEXTGEN Technologies

Targeted M&A

- Acceleration of portfolio transformation
- Expansion of businesses with above-average growth, sustainability profile and returns

Attractive dividend

- Reliable and sustainably growing

Solid investment grade rating

1. 80% of growth capex for Next Generation Solutions (~€350 m p.a.) | 2. Additional capex for Next Generation Technologies (~€65 m p.a. on average)

January 2023 | Evonik Q3 2022 Company Presentation
Capex as key element for investments into handprint & footprint

WE INCREASE OUR HANDPRINT
80% of growth capex for “Next Generation Solutions”

>€3 bn
2022-2030

WE REDUCE OUR FOOTPRINT
Additional capex for “Next Generation Technologies”
mainly on top of maintenance

~€700 m
2022-2030

<table>
<thead>
<tr>
<th>Capex p.a. until FY 2022¹</th>
<th>Capex p.a. post 2022⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td>~€900 m</td>
<td>~50%</td>
</tr>
<tr>
<td>Growth capex</td>
<td>~50%</td>
</tr>
<tr>
<td>Maintenance capex</td>
<td></td>
</tr>
</tbody>
</table>

1. Incl. ~€50 m p.a. for Performance Materials
2. ~€350 m p.a.
3. ~€80 m p.a. on average incl. ~€15 m p.a. for PM, ramping up gradually over the coming years
4. Incl. ~€65 m p.a. for PM
Clear value generation with investments into “Next Generation Solutions” and “Next Generation Technologies”

**NEXTGEN Solutions**

- >50% sales share
- Products with superior sustainability¹ and financial performance

**NEXTGEN Technologies**

- Projects to lower CO₂ emissions with value-enhancing, positive NPVs
- 2030
  - -25%² Scope 1+2

**Target & benefit**

**Value creation**

Clear investment criteria – aligned with strategic, sustainability and financial targets

- Above-average market growth
- Superior sustainability profile (PSA analysis)
- IRR above ROCE target (>11%)
- CO₂ pricing implemented

- €700 m capex (2022-2030) ...
  - For NPV-positive projects
  - For advanced levers, innovative waste heat up-cycling and process re-design

... resulting in >€100 m opex savings (p.a.)

---

¹ “Next Generation Solutions” include “Leader” (A++) and “Driver” (A+) products and solutions
² Commitment letter signed and handed in for SBTi, 25th April 2022, gross emissions reduction with reference year 2021, target year 2030

January 2023 | Evonik Q3 2022 Company Presentation
Spotlight on shareholder returns
Reliable and attractive dividend policy

Dividend (in €) for FY

- Slight increase to €1.17 in FY 2021
- Attractive dividend yield of ~4%
- Reliable dividend policy targeting:
  - Dividend continuity
  - Adj. EPS and FCF growth with potential for sustainable dividend growth going forward
We are consistently and reliably growing EBITDA and Free Cash Flow

Strong earnings growth …

Adj. EBITDA in € m

2017 2018 2019 2020 2021 2022
1,970 2,150 2,153 1,906 2,383 2,500-2,600
5% CAGR

… is translating into even faster FCF growth

Free Cash Flow in € m
(Cash conversion in %)

2017 2018 2019 2020 2021 2022
511 (26%) 526 (24%) 717 (33%) 780 (41%) 950 (40%) (~30%)
15% CAGR

January 2023 | Evonik Q3 2022 Company Presentation
# Table of contents

1. Evonik at a glance
2. Strategy
3. Capital allocation & financial targets
4. Financials Q3 2022
Q3 2022 results at a glance

<table>
<thead>
<tr>
<th>Sales (in € m)</th>
<th>Adj. EBITDA (in € m)</th>
<th>Free cash flow (in € m)</th>
<th>Adj. EPS (in €)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,878</td>
<td>615</td>
<td>288</td>
<td>0.54</td>
</tr>
<tr>
<td>(Q3 2021: 3,871)</td>
<td>(Q3 2021: €645 m)</td>
<td>(Q3 2021: €524 m)</td>
<td>(Q3 2021: 0.58 €)</td>
</tr>
</tbody>
</table>

Volumes decline; another +17% pricing on already elevated prior-year basis

Solid results – Specialty Additives above and Smart Materials on prior-year level

Cash generation picking up thanks to improvement in inventories

Financial result and tax rate in-line with expectations and FY guidance
Solid results in an increasingly challenging environment

- Higher prices again compensate higher variable costs in all divisions
- Lower volumes across majority of businesses impacting earnings

No impact from inventory revaluation in Q3
Adj. EBITDA development by division

**Specialty Additives**
- Q3 21: 224
- Q2 22: 263
- Q3 22: 243

Proving resilience in challenging environment once more

**Nutrition & Care**
- Q3 21: 192
- Q2 22: 185
- Q3 22: 148

Supply chain issues in Health Care and destocking in Animal Nutrition; Care Solutions strong

**Smart Materials**
- Q3 21: 177
- Q2 22: 198
- Q3 22: 177

Strong silica and silanes business compensate lower PA12 volumes and weaker demand for H₂O₂

**Performance Materials**
- Q3 21: 97
- Q2 22: 163
- Q3 22: 74

Spread normalization and maintenance in C4 chain after an exceptional Q2
### Specialty Additives

<table>
<thead>
<tr>
<th>Sales (in € m)</th>
<th>Q3 21</th>
<th>Q2 22</th>
<th>Q3 22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>934</td>
<td>1,116</td>
<td>1,113</td>
</tr>
<tr>
<td>Price</td>
<td></td>
<td>+19%</td>
<td></td>
</tr>
<tr>
<td>FX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>+6%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td>+1%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adj. EBITDA (in € m) / margin (in %)</th>
<th>Q3 21</th>
<th>Q2 22</th>
<th>Q3 22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>224</td>
<td>263</td>
<td>243</td>
</tr>
<tr>
<td>Price</td>
<td>24.0%</td>
<td>23.6%</td>
<td>21.8%</td>
</tr>
<tr>
<td>FX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Overall strong performance across all businesses – demonstrating resilience in tougher environment
- Price increases continue on similar strong level as Q2 (+18% yoy) and compensate for higher variable costs
- Volume declines in Europe and Asia, volume expansion in Americas
  - Good demand in agro, energy storage and release coatings
  - Weaker demand and destocking esp. from coatings and construction
  - Unplanned downtime in Crosslinkers

![Diagram showing sales and EBITDA]
**Nutrition & Care**

**Sales (in € m)**

- Q3 21: 931
- Q2 22: 1,027
- Q3 22: 1,062

**Adj. EBITDA (in € m) / margin (in %)**

- Q3 21: 192 (20.6%)
- Q2 22: 185 (18.0%)
- Q3 22: 148 (13.9%)

**Q3 22 vs. Q3 21**

- Volume: -10%
- Price: +14%
- FX: +9%
- Other: +1%

- **Health & Care:**
  - Care Solutions: Strong volumes and pricing esp. for cosmetic solutions and active cosmetic ingredients
  - Health Care: weak quarter with supply chain issues at several sites resulting in lower deliveries to customers, catch-up in Q4

- **Animal Nutrition:**
  - Only slow demand recovery in Q3 (qoq)
  - Ongoing customer destocking across all regions and impact of global inflation on meat consumption in low-income countries
- Stable volumes despite weaker demand in construction and limitations in raw materials for PA12 (C4 maintenance)
- Continued strong growth in Silanes and Silica, driven by automotive demand, oral care, electronics and special oxides
- Active Oxygen’s base business affected by current gas price
- High demand for “Eco-Solutions” like active oxygen specialties and gas separation membranes
- Price increases in same magnitude as previous quarter, continue to compensate higher variable costs
Lower earnings after exceptional Q2 driven by lower volumes in C4 business: Planned maintenance shutdown in Marl followed by force majeure of a supplier

- Weaker development across all C4 market segments, most pronounced in INA and plasticizers (lower demand from construction and automotive)

- C4 spreads down from peak levels, additional margin impact from lower Naphtha price and increased energy costs
Revenue up +146% yoy (to €541 m) due to energy purchasing for third parties (pass-through to customers, no effect on earnings)

Adj. EBITDA clearly better yoy and qoq due to re-distribution of negative effects (esp. higher costs for power plants and energy purchasing) in Q2 to operating businesses
Improving cash generation despite continued NWC headwinds

- **Cash generation picking up in Q3** and pointing into the right direction – despite significant NWC headwind
- **Implemented inventory optimization measures** starting to take effect and set to continue in Q4
- After 9M 2022, free cash flow remains heavily impacted by **significantly higher NWC outflow yoy**
- Additionally, yoy higher cash outflow for variable remuneration (in Q2 2022 for FY 2021)
Resilient & regionally balanced portfolio setup
- Support from sustainability focus and defensive end markets
- Contribution from new PA12 plant
- Diversified, global asset footprint
- Competitive European operations

Progress in Performance Materials divestment
- Divestment projects progressing as planned
- Aiming to find new owners/partners in the course of 2023
- Reducing exposure to Europe

High visibility on energy costs and gas supply
- Good visibility on energy cost development – independent from political decisions
- Energy supply well secured
- Raw material & logistics costs beyond peak level

Contingency measure toolbox in implementation
- Triple-digit million € additional cost savings
- Proven cash generation also in tougher times (41% conversion in 2020)
- Strong balance sheet and liquidity position
Support from sustainability focus & defensive end markets
Also in 2023 – largely independent of general macro trends

Additives that make the sustainable difference

Renewable energy production
- Growth driver: Increasing number of wind farms
e.g. Crosslinkers for composite materials in wind turbine blades
  e.g. Oil Additives for wind turbine gear oils

Defensive end markets
- Earnings growth 2023 expected for both Care Solutions and Health Care

Strong growth from biotech platform
- Ceramides, cell culture and CDMO projects as growth drivers

New capacities
- >50% capacity increase in attractive market
  creating the world’s largest fully integrated PA12 network in Marl

PA12: New capacities into favorable end markets

Various applications
- >400 specific compounds and tailor-made formulations
Balanced global footprint – Clearly profitable in all regions
Europe as profitable core region for Evonik

Share of production volumes (in kt, FY 2021)\(^1\)

- **Americas**: \(~30\%\)
- **Europe**: \(~40\%\)
- **Asia-Pacific**: \(~30\%\)

European business with high competitiveness

- **Portfolio**
  - Focus on less energy-intensive businesses
  - Frontrunner in sustainability

- **Innovation**
  - Innovation-driven, customer-centric solutions
  - Value-based pricing

- All major value chains with production hubs in all three key regions

- Clearly profitable across all value chains in Europe – now and in the future

---

1. Excl. Performance Materials
High visibility on energy costs and gas supply
Independent from political decisions

Evonik-specific advantages

Long-term hedging strategy

Gas substitution measures (up to 40% natural gas in Germany)

We are in control:

- Cost increase 2023 will be below the increase of 2022
- Security on energy supply and costs largely independent from political decisions

Energy costs (in € m)

<table>
<thead>
<tr>
<th>Year</th>
<th>Energy Costs (€ m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>700</td>
</tr>
<tr>
<td>2022E</td>
<td>~1,300</td>
</tr>
<tr>
<td>2023E¹</td>
<td>~1,600</td>
</tr>
</tbody>
</table>

1. Excluding potential impact from gas price cap in Germany
**Contingency measure toolbox in implementation**

**Triple-digit million € additional cost savings in 2023**

<table>
<thead>
<tr>
<th>Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Reduce fixed cost base</td>
</tr>
<tr>
<td>- Capex discipline</td>
</tr>
<tr>
<td>- Strict NWC management</td>
</tr>
<tr>
<td>- Optimized maintenance schedules</td>
</tr>
<tr>
<td>- Discipline on projects with no immediate business impacts</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Discipline on hiring &amp; secondments</td>
</tr>
<tr>
<td>- Less business travel</td>
</tr>
<tr>
<td>- Discipline on wage increases and promotions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Less use of consultants</td>
</tr>
<tr>
<td>- Reduced fair and event participation</td>
</tr>
<tr>
<td>- Review of non-contracted sponsoring</td>
</tr>
</tbody>
</table>

**Learnings from 2020:**

- Contingency measure toolbox ready
- Will be executed immediately

**January 2023 | Evonik Q3 2022 Company Presentation**
FY 2022 outlook for adj. EBITDA “between €2.5 and 2.6 bn” confirmed

“Adj. EBITDA between €2.5 and 2.6 bn”

<table>
<thead>
<tr>
<th>Year</th>
<th>Adjusted EBITDA (€m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2,383</td>
</tr>
<tr>
<td>2022E</td>
<td>€2.5-2.6 bn</td>
</tr>
</tbody>
</table>

Basis for the outlook

- Strong 9M performance as basis (+10% yoy)
- Assuming similar pace of macro slowdown for Q4 like in Q3
- Energy supply:
  - Outlook based on sufficient gas supply to maintain production on necessary scale
  - Extensive measures implemented to make energy production at European sites largely independent from Russian gas
NWC impact in 2022 so far

- ~€1 bn NWC outflow in 9M (yoy delta of ~€500 m) driven mainly by inventories and payables
- Inventory optimization measures started to take effect in Q3 and will continue in Q4

Outlook

- Significant NWC improvement expected in Q4
- Leaving additional NWC reversal potential in 2023 to return to 40% cash conversion

1. Free cash flow conversion (FCF/adj. EBITDA)
Evonik with structural cash generation improvement – above peers

FCF conversion (in %)\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>Peers(^2)</th>
<th>Evonik</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>35</td>
<td>22</td>
</tr>
<tr>
<td>2018</td>
<td>33</td>
<td>24</td>
</tr>
<tr>
<td>2019</td>
<td>36</td>
<td>33</td>
</tr>
<tr>
<td>2020</td>
<td>33</td>
<td>41</td>
</tr>
<tr>
<td>2021</td>
<td>23</td>
<td>40</td>
</tr>
<tr>
<td>2022E(^3)</td>
<td>18</td>
<td>~30</td>
</tr>
<tr>
<td>2023E</td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>

- 40% target achieved ahead of time
- Above peers despite NWC burden
- Targeting return to 40%

2017-2021: ~15% FCF CAGR

---


January 2023 | Evonik Q3 2022 Company Presentation
### Additional indications for FY 2022

| **Sales** | around €18.5 bn (previously: between €17 and 18 bn; 2021: €15.0 bn) |
| **ROCE** | slightly above the level of 2021 (unchanged; 2021: 9.0%) |
| **Capex** | around €900 m (unchanged; 2021: €865 m) |
| **EUR/USD sensitivity** | +/- 1 USD cent = +/- ~€6 m adj. EBITDA (FY basis) |
| **Adj. EBITDA T&I/Other** | considerably less negative than prior year level (unchanged; 2021: -€221 m) |
| **Adj. D&A** | slightly above the level of 2021 (unchanged; 2021: €1,045 m) |
| **Adj. net financial result** | slightly less negative than 2021 (unchanged; 2021: -€97 m) |
| **Adj. tax rate** | around long-term sustainable level of ~30% (unchanged; FY 2021: 28%); higher compared to previous years, amongst others due to changes in international tax legislation |

---

1. Cash outflow for investment in intangible assets, pp&e
2. Including transaction effects (after hedging) and translation effects; before secondary / market effects

---

January 2023 | Evonik Q3 2022 Company Presentation
### Indications for adj. EBITDA FY 2022 on division level

<table>
<thead>
<tr>
<th>Specialty Additives</th>
<th>Nutrition &amp; Care</th>
<th>Smart Materials</th>
<th>Performance Materials</th>
</tr>
</thead>
</table>
|  - Mission-critical solutions with superior sustainability profile supporting broad-based growth across additives portfolio  
  - Pricing initiatives continue to compensate higher input costs |  - Increasing share of “System Solutions” with above-average margin profile  
  - Positive price trend in Animal Nutrition  
  - Continued active cost & portfolio management |  - Ongoing positive development in “Eco Solutions”  
  - Inorganics as key driver of positive earnings trajectory  
  - Pricing initiatives continue to compensate higher input costs |  - Product spreads in C4 chain with clearly positive trends  
  - Superabsorber to benefit from improving market environment and long-term customer relationships |

- “slightly above prior year level” (unchanged)  
- “on prior year level” (previously: considerably above PY)  
- “considerably above prior year level” (unchanged)  
- “significantly above prior year level” (unchanged)
Evonik energy and gas consumption

Total procurement volume

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Logistics</td>
<td>~20%</td>
</tr>
<tr>
<td>Energy</td>
<td>~30%</td>
</tr>
<tr>
<td>Raw materials</td>
<td>~10%</td>
</tr>
<tr>
<td>Machinery &amp; Equipment</td>
<td>~20%</td>
</tr>
<tr>
<td>Others</td>
<td>~5%</td>
</tr>
<tr>
<td>Total</td>
<td>~100%</td>
</tr>
</tbody>
</table>

Thereof: Energy

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electricity</td>
<td>~19TWh</td>
</tr>
<tr>
<td>Coal</td>
<td>~4TWh</td>
</tr>
<tr>
<td>Natural gas</td>
<td>~19TWh</td>
</tr>
<tr>
<td>Rest of World</td>
<td>~5TWh</td>
</tr>
<tr>
<td>APAC</td>
<td>~3TWh</td>
</tr>
<tr>
<td>Germany</td>
<td>~5TWh</td>
</tr>
<tr>
<td>North America</td>
<td>~3TWh</td>
</tr>
<tr>
<td>Rest of Europe</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Total</td>
<td>~19TWh</td>
</tr>
</tbody>
</table>

Total gas consumption

<table>
<thead>
<tr>
<th>Region</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>~15TWh</td>
</tr>
<tr>
<td>Rest of World</td>
<td>~5TWh</td>
</tr>
<tr>
<td>North America</td>
<td>~2TWh</td>
</tr>
<tr>
<td>APAC</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Rest of Europe</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Other German sites</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Antwerp</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Marl</td>
<td>~1TWh</td>
</tr>
<tr>
<td>Other European sites</td>
<td>~1TWh</td>
</tr>
</tbody>
</table>
### Adjusted income statement Q3 2022

<table>
<thead>
<tr>
<th></th>
<th>Q3 2021</th>
<th>Q3 2022</th>
<th>Δ in %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sales</strong></td>
<td>3,871</td>
<td>4,878</td>
<td>+26</td>
</tr>
<tr>
<td><strong>Adj. EBITDA</strong></td>
<td>645</td>
<td>615</td>
<td>-5</td>
</tr>
<tr>
<td>Depreciation &amp; amortization</td>
<td>-258</td>
<td>-273</td>
<td></td>
</tr>
<tr>
<td><strong>Adj. EBIT</strong></td>
<td>387</td>
<td>342</td>
<td>-12</td>
</tr>
<tr>
<td>Adj. net financial result</td>
<td>-37</td>
<td>-21</td>
<td></td>
</tr>
<tr>
<td>D&amp;A on intangible assets</td>
<td>37</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td><strong>Adj. income before income taxes</strong></td>
<td>387</td>
<td>360</td>
<td>-7</td>
</tr>
<tr>
<td>Adj. income tax</td>
<td>-113</td>
<td>-106</td>
<td></td>
</tr>
<tr>
<td><strong>Adj. income after taxes</strong></td>
<td>274</td>
<td>254</td>
<td>-7</td>
</tr>
<tr>
<td>Adj. non-controlling interests</td>
<td>-5</td>
<td>-1</td>
<td></td>
</tr>
<tr>
<td><strong>Adj. net income</strong></td>
<td>269</td>
<td>253</td>
<td>-6</td>
</tr>
<tr>
<td><strong>Adj. earnings per share</strong></td>
<td>0.58</td>
<td>0.54</td>
<td></td>
</tr>
<tr>
<td>Adjustments</td>
<td>-14</td>
<td>-16</td>
<td></td>
</tr>
</tbody>
</table>

### Adj. net financial result (-€21 m)
- Higher interest income, mainly due to higher discount rate on other provisions

### Adj. tax rate (29%)
- Slightly below FY guidance of 30%

### Adjustments (-€16 m)
- Restructuring: mainly charges related to the intended divestment of Performance Materials
- M&A: Integration of previous acquisitions
## Cash flow statement Q3 2022

<table>
<thead>
<tr>
<th>in € m</th>
<th>Q3 2021</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income before financial result and income taxes (EBIT)</td>
<td>373</td>
<td>326</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>260</td>
<td>275</td>
</tr>
<tr>
<td>Δ Net working capital</td>
<td>-159</td>
<td>-115</td>
</tr>
<tr>
<td>Change in provisions for pensions &amp; other post-employment benefits</td>
<td>10</td>
<td>-5</td>
</tr>
<tr>
<td>Change in other provisions</td>
<td>163</td>
<td>85</td>
</tr>
<tr>
<td>Change in miscellaneous assets/liabilities</td>
<td>40</td>
<td>12</td>
</tr>
<tr>
<td>Cash in- and outflows from income taxes</td>
<td>15</td>
<td>-59</td>
</tr>
<tr>
<td>Others</td>
<td>-1</td>
<td>-2</td>
</tr>
<tr>
<td><strong>Cash flow from operating activities (continuing ops.)</strong></td>
<td><strong>701</strong></td>
<td><strong>517</strong></td>
</tr>
<tr>
<td>Cash outflows for investment in intangible assets, pp&amp;e</td>
<td>-177</td>
<td>-229</td>
</tr>
<tr>
<td><strong>FCF</strong></td>
<td><strong>524</strong></td>
<td><strong>288</strong></td>
</tr>
<tr>
<td><strong>Cash flow from investing activities (continuing ops.)</strong></td>
<td><strong>-315</strong></td>
<td><strong>-188</strong></td>
</tr>
<tr>
<td><strong>Cash flow from financing activities (continuing ops.)</strong></td>
<td><strong>-83</strong></td>
<td>27</td>
</tr>
</tbody>
</table>

### CF from operating activities (€517 m)
- Lower NWC outflow yoy, following substantially higher yoy outflow in Q1 & Q2 (>€400 m each)
- Other provisions: yoy lower contribution to bonus provisions
- Normalized tax payment after inflow in last year

### CF from investing activities (-€188 m)
- Capex catching-up after yoy lower outflows in Q1 and Q2
- Inflow from sale of securities

### CF from financing activities (€27 m)
- Inflow from Schuldschein largely compensated by outflow for other financing activities
Net financial debt development Q3 2022

(in € m)

3,836
-517
229
193
66
3,807

30.06.2022 Net financial debt

CF from operating activities (cont. op.)
Cash outflows for investments in intangibles and PP&E
Change in lease liabilities¹
Other²
30.09.2022 Net financial debt

1. Attributable to the new gas power plant in Marl
2. Incl. outflows for financial transactions and interest payments
Development of net debt and leverage over time

(in € m)

Net financial debt (€3,807 m)
- Basically unchanged vs. last quarter-end
- Still low net financial debt leverage at 1.4x

Pension provisions (€1,655 m)
- Long-dated pension obligations with >18 years duration
- Further slight decline in Q3 due to another increase of pension discount rates (German pension discount rate increase from 3.3% to 3.9%)
- Pension provisions partly balanced by corresponding deferred tax assets of ~€0.7 bn

- Adj. net debt / adj. EBITDA
- 2. Net financial debt – 50% hybrid bond + pension provisions
- 3. (Net financial debt – 50% hybrid bond) / adj. EBITDA

---

1. Adj. net debt / adj. EBITDA
2. Net financial debt – 50% hybrid bond + pension provisions
3. (Net financial debt – 50% hybrid bond) / adj. EBITDA
### Divisional overview by quarter

<table>
<thead>
<tr>
<th>Sales (in € m)</th>
<th>Q1/21</th>
<th>Q2/21</th>
<th>Q3/21</th>
<th>Q4/21</th>
<th>FY 2021</th>
<th>Q1/22</th>
<th>Q2/22</th>
<th>Q3/22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialty Additives</td>
<td>907</td>
<td>922</td>
<td>934</td>
<td>947</td>
<td>3,710</td>
<td>1,049</td>
<td>1,116</td>
<td>1,113</td>
</tr>
<tr>
<td>Nutrition &amp; Care</td>
<td>780</td>
<td>838</td>
<td>931</td>
<td>1,008</td>
<td>3,557</td>
<td>1,038</td>
<td>1,027</td>
<td>1,062</td>
</tr>
<tr>
<td>Smart Materials</td>
<td>909</td>
<td>975</td>
<td>1,002</td>
<td>1,032</td>
<td>3,918</td>
<td>1,181</td>
<td>1,237</td>
<td>1,259</td>
</tr>
<tr>
<td>Performance Materials</td>
<td>580</td>
<td>708</td>
<td>784</td>
<td>840</td>
<td>2,911</td>
<td>947</td>
<td>1,043</td>
<td>903</td>
</tr>
<tr>
<td>Technology &amp; Infrastructure (T&amp;I) / Other</td>
<td>182</td>
<td>193</td>
<td>220</td>
<td>264</td>
<td>859</td>
<td>283</td>
<td>349</td>
<td>541</td>
</tr>
<tr>
<td><strong>Evonik Group</strong></td>
<td>3,358</td>
<td>3,636</td>
<td>3,871</td>
<td>4,091</td>
<td>14,955</td>
<td>4,498</td>
<td>4,772</td>
<td>4,878</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adj. EBITDA (in € m)</th>
<th>Q1/21</th>
<th>Q2/21</th>
<th>Q3/21</th>
<th>Q4/21</th>
<th>FY 2021</th>
<th>Q1/22</th>
<th>Q2/22</th>
<th>Q3/22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specialty Additives</td>
<td>273</td>
<td>242</td>
<td>224</td>
<td>181</td>
<td>920</td>
<td>252</td>
<td>263</td>
<td>243</td>
</tr>
<tr>
<td>Nutrition &amp; Care</td>
<td>143</td>
<td>183</td>
<td>192</td>
<td>200</td>
<td>717</td>
<td>222</td>
<td>185</td>
<td>148</td>
</tr>
<tr>
<td>Smart Materials</td>
<td>173</td>
<td>176</td>
<td>177</td>
<td>123</td>
<td>650</td>
<td>197</td>
<td>198</td>
<td>177</td>
</tr>
<tr>
<td>Performance Materials</td>
<td>42</td>
<td>99</td>
<td>97</td>
<td>80</td>
<td>317</td>
<td>97</td>
<td>163</td>
<td>74</td>
</tr>
<tr>
<td>Technology &amp; Infrastructure (T&amp;I) / Other</td>
<td>-43</td>
<td>-51</td>
<td>-45</td>
<td>-82</td>
<td>-221</td>
<td>-33</td>
<td>-81</td>
<td>-27</td>
</tr>
<tr>
<td><strong>Evonik Group</strong></td>
<td>588</td>
<td>649</td>
<td>645</td>
<td>502</td>
<td>2,383</td>
<td>735</td>
<td>728</td>
<td>615</td>
</tr>
</tbody>
</table>
## Upcoming IR events

### Conferences & roadshows

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 6, 2023</td>
<td>Oddo BHF Forum, Lyon</td>
</tr>
<tr>
<td>January 10, 2023</td>
<td>Commerzbank &amp; Oddo BHF German Investment Seminar, New York</td>
</tr>
<tr>
<td>January 17, 2023</td>
<td>Kepler Cheuvreux German Corporate Conference, Frankfurt</td>
</tr>
</tbody>
</table>

### Upcoming reporting dates

<table>
<thead>
<tr>
<th>Date</th>
<th>Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2, 2023</td>
<td>Q4 / FY 2022 Reporting</td>
</tr>
<tr>
<td>May 9, 2023</td>
<td>Q1 2023 Reporting</td>
</tr>
<tr>
<td>May 31, 2023</td>
<td>Annual General Meeting</td>
</tr>
<tr>
<td>August 4, 2023</td>
<td>Q2 2023 Reporting</td>
</tr>
<tr>
<td>November 7, 2023</td>
<td>Q3 2023 Reporting</td>
</tr>
</tbody>
</table>
Disclaimer

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.